Pablo Cabral
Executive Director External Innovation Eli Lilly & Co.
Seminars
Wednesday 18th March 2026
Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?
10:30 am
- Balancing innovation with clinical feasibility and scalable development in kidney disease
- Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
- Exploring whether targeted delivery strategies must be disease-specific to maximize impact
- Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown
Tuesday 17th March 2026
Panel Discussion: Advancing Drug Development in Cardiovascular-Kidney-Metabolic (CKM) Syndrome
8:00 am
- Explore our evolving understanding of the pathophysiology linking cardiovascular, kidney and metabolic disorders
- Identify when and how overlapping CKM phenotypes can be leveraged to design more efficient clinical trials
- Discuss next steps in integrated drug development and regulatory frameworks for CKM components with shared mechanistic drivers
